Skip to main content
Xspray Pharma logo

Xspray Pharma — Investor Relations & Filings

Ticker · XSPRAY ISIN · SE0023312764 LEI · 549300NGRQCNZ3X4L157 ST Manufacturing
Open in API
Filings indexed 254 across all filing types
Latest filing 2024-04-19 Capital/Financing Update
Country SE Sweden
Listing ST XSPRAY

About Xspray Pharma

https://xspraypharma.com/

Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.

Recent filings

Filing Released Lang Actions
Xspray Pharma erhåller avsiktsförklaring från Östersjöstiftelsen avseende teckning av TO6
Capital/Financing Update Classification · 98% confidence The document is a press release from Xspray Pharma announcing that a major shareholder (Östersjöstiftelsen) has issued a letter of intent to subscribe for new shares via their existing warrants (TO6). This action relates directly to the company's capital structure and fundraising efforts, specifically concerning the exercise of warrants which will inject capital (125.5 MSEK). This fits the definition of 'Capital/Financing Update' (CAP). Although it involves share subscription, it is an announcement about the intent to raise capital, not a general share issue (SHA) or a transaction in own shares (POS) in the context of a buyback program. Since it is a specific announcement about financing activity, CAP is the most appropriate code.
2024-04-19 Swedish
Xspray Pharma receives declaration of intent from Östersjöstiftelsen regarding exercise of TO6 warrants
Capital/Financing Update Classification · 98% confidence The document announces that Xspray Pharma has received a declaration of intent from a major shareholder (Östersjöstiftelsen) regarding the exercise of TO6 warrants to subscribe for new shares, which will raise capital for the company. This directly relates to fundraising and capital structure changes. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document is short and announces an event/action related to financing, not a comprehensive financial report.
2024-04-19 English
Notice of annual general meeting of Xspray Pharma AB (publ)
AGM Information Classification · 100% confidence The document explicitly begins with the title "Notice of annual general meeting of Xspray Pharma AB (publ)". It details the date, time, location, registration procedures, and the proposed agenda for the meeting. The agenda items cover the election of the chairman, board members, auditors, remuneration, and resolutions on incentive programs and capital structure changes, which are all standard components of an Annual General Meeting (AGM) notice. This directly corresponds to the definition of AGM Information (AGM-R).
2024-04-18 English
Kallelse till årsstämma i Xspray Pharma AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i Xspray Pharma AB (publ)" which translates to "Notice of Annual General Meeting in Xspray Pharma AB (publ)". The text details the date, time, location, registration procedures, agenda items (including election of board members, approval of remuneration report, and proposals for incentive programs), and voting rights for a general meeting. This content is characteristic of a formal notice calling shareholders to an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2024-04-18 Swedish
Xspray Pharma receives declarations of intent from its largest owners regarding exercise of TO6 warrants
Share Issue/Capital Change Classification · 99% confidence The document is a short announcement regarding the intent of major shareholders to exercise warrants (TO6) to subscribe for new shares, which will result in gross proceeds of SEK 125.5 million if fully subscribed. This directly relates to the company's financing activities and capital structure changes (issuing new shares upon warrant exercise). This fits best under the 'Capital/Financing Update' category (CAP). Although it mentions the publication of information under EU Market Abuse Regulation, the core content is a financing update, not just an announcement of a report's release (RPA/RNS). The document length is short (2819 chars), but the content is substantive regarding financing, making CAP more appropriate than RPA or RNS.
2024-04-10 English
Xspray Pharma erhåller avsiktsförklaringar från storägare avseende teckning av TO6
Capital/Financing Update Classification · 98% confidence The document is a short announcement (3023 characters) in Swedish regarding Xspray Pharma receiving letters of intent (avsiktsförklaringar) from major shareholders to subscribe to newly issued warrants (TO6). This relates directly to a financing activity (subscription to warrants to secure funding for commercialization plans). This fits the definition of 'Capital/Financing Update' (CAP). Although it is an announcement, it is not announcing the publication of a full report (like 10-K or IR), but rather a specific corporate action related to capital structure/fundraising, making CAP more specific than the general RPA or RNS fallback.
2024-04-10 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.